PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 30, 2026Lara D. Veeken0 citations

E110 Abdominal pain in dermatomyositis

View Full Paper
BBBodhibrata BanerjeeRTRiya TyagiRNRitambhra Nada

Key Points

  • To highlight the complications associated with anti-NXP2 dermatomyositis, particularly gastrointestinal vasculitis.
  • Case report of a 32-year-old woman with symptoms of dermatomyositis and abdominal complications.
  • Laboratory tests including creatine kinase, lactate dehydrogenase, and aspartate aminotransferase were assessed.
  • Treatment involved intravenous immunoglobulin, mycophenolate mofetil, and rituximab.
  • Patient experienced severe abdominal pain and significant weight loss during the course of treatment.
  • CT enterography indicated small-bowel thickening due to vasculitis.
  • Despite medical interventions and surgery, patient succumbed to refractory shock.

Abstract

Abstract Background/Aims Dermatomyositis (DM) is a group of inflammatory myositis characterised by proximal muscle weakness, cutaneous manifestations, and multisystem involvement. Anti-nuclear matrix protein-2 (anti-NXP2) defines a distinctive clinical subset accounting for approximately 20-25% of adult DM cases. Anti-NXP2 positivity confers a severe disease phenotype with marked muscle weakness, frequent neck flexor and distal limb involvement, dysphagia, subcutaneous oedema, and a higher propensity for calcinosis compared to other DM subtypes. Visceral vasculitis—particularly gastrointestinal (GI) involvement—represents one of the most catastrophic complications in this subset, with reported mortality exceeding 40% Methods A 32-year-old woman presented with photosensitive facial rash and progressive proximal weakness. Laboratory tests showed raised creatine kinase, lactate dehydrogenase and aspartate aminotransferase with positive anti-NXP2 antibody. She received intravenous methylprednisolone pulses and intravenous immunoglobulin followed by mycophenolate mofetil. However, her weakness flared on tapering prednisolone below 20 mg/day. Four months later, she developed dysphagia, dysphonia and dyspnoea (mMRC 3). She was again given methylprednisolone pulses followed by intravenous cyclophosphamide, with which she had partial improvement in her weakness. However, her skin rashes persisted and tofacitinib was added. Six months into the illness, she developed persistent post-prandial abdominal pain and vomiting, followed by the development of new rash, neck and cubital ulcers. There was also 8kg weight loss. On current admission, she had severe proximal muscle weakness, anaemia, neutrophilic leucocytosis, thrombocytopenia, mild transaminitis, ESR 86 mm/hour and CRP 92 mg/L. CT enterography revealed long-segment small-bowel thickening. She was advised to undergo bowel rest, and methylprednisolone pulses were started along with rituximab and tacrolimus. Results In hospital, she developed massive per-rectal bleeding and abdominal rigidity. Exploratory laparotomy revealed a 1cm D2 perforation. Histopathology of the excised tissue demonstrated transmural inflammation with fibrinoid necrosis and break in the internal elastic lamina, confirming vasculitis. Despite surgery and intensive care, she succumbed to refractory shock. Conclusion Anti-NXP2 dermatomyositis represents a high-stakes myositis phenotype in which gastrointestinal vasculitis may transform an otherwise controllable disease into a fulminant, life-threatening emergency. Vigilant surveillance and timely, targeted immunomodulation remain the key to improving survival in this formidable subgroup. Disclosure B. Banerjee: None. R. Tyagi: None. R. Nada: None. V. Dhir: None.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Banerjee et al. (2026) studied this question.

synapsesocial.com/papers/69f2a4f18c0f03fd677641b3https://doi.org/10.1093/rheumatology/keag121.333
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Gastrointestinal involvement in dermatomyositis: multicentric retrospective cohort study2026
  2. 2A case of anti-nuclear matrix protein 2 antibody-positive dermatomyositis sine dermatitis with a challenging diagnosis due to the absence of typical skin manifestations2026
  3. 3Association of Dermatomyositis Sine Dermatitis With Anti–Nuclear Matrix Protein 2 Autoantibodies2020 · 70 citations
  4. 4P024 Dermatomyositis, a blurred clinical picture2024 · 1 citations
  5. 5An unusual presentation of dermatomyositis: dermatomyositis sine dermatitis presenting with rapidly progressive myositis2024 · 1 citations